7th Annual Meeting of the International Cytokine & Interferon Society

20 - 23 October 2019

Hofburg Conference Center, Vienna, Austria

www.vienna.cytokinesociety.org
LEGENDplex™

One Assay, Multiple Analytes.

Quantifying multiple biomarkers should be easy. LEGENDplex™ multiplex panels reliably and accurately generate more data, in less time, with just one assay.

- Specifically designed for use with standard flow cytometers
- Free data analysis software included with every assay
- Human, mouse, rat, and non-human primate specificities
- Expanding list of analyte targets
- Flexible ordering formats

Visit: biolegend.com/legendplex

BioLegend is ISO 13485:2016 Certified
Toll-Free Tel (US & Canada): 1.877.BIOLEGEND (246.5343)
Tel: 858.768.5800
biolegend.com

08-0075-12
# Table of Contents

Welcome Message 04

Committee Members 04

List of Invited Speakers 06

General Information 07

Networking Events 08

Program Overview 10 - 12
- Sunday 20 October 10
- Monday 21 October 10
- Tuesday 22 October 11
- Wednesday 23 October 12

Scientific Program 13 - 23
- Sunday 20 October 13
- Monday 21 October 14 - 16
- Tuesday 22 October 17 - 19
- Wednesday 23 October 20 - 23

Posters 26 - 39
- Poster Session 1: Monday 21 October 26 - 31
- Poster Session 2: Tuesday 22 October 34 - 39

Award Winners 32

Company Profiles 41 - 45

Layout of Venue & Exhibition Area 47

Acknowledgements 48
Welcome Message

Dear Colleagues,

We would like to welcome you to the 7th Annual Meeting of the International Cytokine & Interferon Society (ICIS) in Vienna.

The ICIS annual meeting has become the world’s most important annual conference on basic, clinical and translational research on cytokines and their roles in host defense, inflammation, tissue repair and cancer.

Cytokine targeting is one of the greatest revolutions in modern medicine. A large number of severe and sometimes even lethal inflammatory and autoimmune diseases have become manageable due to selective inhibition of cytokines and cytokine signaling. The development of compounds that selectively inhibit cytokines or interferons has permitted an so far unprecedented molecular characterization of human disease. Cytokines also contribute to cancer development and alterations in tissue homeostasis. Cytokines 2019 addresses these developments and provides a comprehensive picture of the current knowledge of cytokine pathways in human disease and the strategies to inhibit, modulate or foster cytokine responses.

We believe this will be a fantastic meeting in the beautiful city of Vienna with many networking opportunities and hope that you make the most of the opportunities it provides.

We wish you a successful meeting!

Georg Schett
Chairman of Cytokines 2019

Committee Members

SCIENTIFIC ORGANIZING COMMITTEE

Georg Schett
University of Erlangen-Nuremberg
Germany

Leo Joosten
University of Nijmegen
The Netherlands

Mariana J. Kaplan
National Institute of Arthritis, Musculoskeletal and Skin Diseases
USA

Stefan Rose-John
University of Kiel
Germany

Yoshiya Tanaka
University of Occupational and Environmental Health, Kitakyushu-shi, Fukuoka, Japan

SCIENTIFIC ADVISORY BOARD

Thomas Decker (AT)
Kate Fitzgerald (US)
Richard Flavell (US)
Cem Gabay (CH)
Sarah Gaffen (US)
Brendan Jenkins (AU)
Simon Jones (UK)
Anne O’Garra (UK)
Nancy Reich (US)
Josef Schwarzmeier (AT)
Akinori Takaoka (JP)
Kazuhiko Yamamoto (JP)
LUNARIS™ Technology

Where are your limits? Multiplex insights from as little as 3 µL sample

FIND OUT MORE

Visit us at booth #11 to discuss your research needs

www.ayoxxa.com
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution and Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stuart Allan</td>
<td>University of Manchester, UK</td>
</tr>
<tr>
<td>Francesca Barone</td>
<td>Queen Elisabeth Hospital, UK</td>
</tr>
<tr>
<td>Burkhard Becher</td>
<td>University of Zurich, CH</td>
</tr>
<tr>
<td>Andreas Bergthaler</td>
<td>CeMM Research Center for Molecular Medicine, AT</td>
</tr>
<tr>
<td>Aline Bozec</td>
<td>University of Erlangen-Nuremberg, DE</td>
</tr>
<tr>
<td>Gordon Brown</td>
<td>University of Exeter, UK</td>
</tr>
<tr>
<td>Chris Buckley</td>
<td>Queen Elisabeth Hospital, UK</td>
</tr>
<tr>
<td>Jane Buckner</td>
<td>Benaroya Research Institute, US</td>
</tr>
<tr>
<td>Tom Cupedo</td>
<td>Erasmus University Medical Center, NL</td>
</tr>
<tr>
<td>Thomas Decker</td>
<td>University of Vienna, AT</td>
</tr>
<tr>
<td>Chen Dong</td>
<td>BioLegend William E. Paul Award</td>
</tr>
<tr>
<td></td>
<td>Tsinghua University, CN</td>
</tr>
<tr>
<td>Dirk Elewaut</td>
<td>Ghent University, BE</td>
</tr>
<tr>
<td>Cem Gabay</td>
<td>University Hospitals of Geneva, CH</td>
</tr>
<tr>
<td>Sarah Gaffen</td>
<td>University of Pittsburgh, US</td>
</tr>
<tr>
<td>Raphaela Goldbach Mansky</td>
<td>NIAID/DIR, US</td>
</tr>
<tr>
<td>Romina Goldszmid</td>
<td>NIH, US</td>
</tr>
<tr>
<td>Johann Guddronsson</td>
<td>University of Michigan, US</td>
</tr>
<tr>
<td>Lucie Heinzerling</td>
<td>University of Erlangen-Nuremberg, DE</td>
</tr>
<tr>
<td>John Isaacs</td>
<td>Newcastle University, UK</td>
</tr>
<tr>
<td>Shintaro Iwama</td>
<td>Nagoya University Hospital, JP</td>
</tr>
<tr>
<td>Akiko Iwasaki, Milstein Award</td>
<td>Yale University, US</td>
</tr>
<tr>
<td>Brendan Jenkins</td>
<td>Monash Institute of Medical Research, AU</td>
</tr>
<tr>
<td>Simon Jones</td>
<td>Cardiff University, UK</td>
</tr>
<tr>
<td>Kenji Kabashima</td>
<td>Kyoto University, JP</td>
</tr>
<tr>
<td>Yuko Kaneko</td>
<td>Keio University, JP</td>
</tr>
<tr>
<td>Thomas Korn</td>
<td>Technical University of Munich, DE</td>
</tr>
<tr>
<td>Michaela Kress</td>
<td>Medical University of Innsbruck, AT</td>
</tr>
<tr>
<td>Gerhard Könke</td>
<td>University of Erlangen-Nuremberg, DE</td>
</tr>
<tr>
<td>Atushi Kumanogo</td>
<td>Osaka University, JP</td>
</tr>
<tr>
<td>Ed Lavelle</td>
<td>Trinity College Dublin, IE</td>
</tr>
<tr>
<td>Lydia Lynch, Keynote Speaker</td>
<td>Trinity College Dublin, IE</td>
</tr>
<tr>
<td>Tracy L. McGaha</td>
<td>Princess Margaret Cancer Centre, CA</td>
</tr>
<tr>
<td>Anne O’Garra</td>
<td>The Francis Crick Institute, UK</td>
</tr>
<tr>
<td>Taku Okazaki</td>
<td>University of Tokushima, JP</td>
</tr>
<tr>
<td>Andreas Ramming</td>
<td>University of Erlangen-Nuremberg, DE</td>
</tr>
<tr>
<td>Nancy Reich</td>
<td>Stony Brook University, US</td>
</tr>
<tr>
<td>Stefan Rose-John</td>
<td>University of Kiel, DE</td>
</tr>
<tr>
<td>Anna Rubartelli</td>
<td>Hospital San Martino, IT</td>
</tr>
<tr>
<td>Georg Schett</td>
<td>University of Erlangen-Nuremberg, DE</td>
</tr>
<tr>
<td>Brigitta Stockinger</td>
<td>The Francis Crick Institute, UK</td>
</tr>
<tr>
<td>Tsutomu Takeuchi</td>
<td>Keio University, JP</td>
</tr>
<tr>
<td>Peter Taylor</td>
<td>University of Oxford, UK</td>
</tr>
<tr>
<td>Diamant Thaci</td>
<td>University of Schleswig-Holstein, DE</td>
</tr>
<tr>
<td>Irina Udalova</td>
<td>University of Oxford, UK</td>
</tr>
<tr>
<td>David Voehringer</td>
<td>University of Erlangen-Nuremberg, DE</td>
</tr>
<tr>
<td>Erwin Wagner</td>
<td>Medical University of Vienna, AT</td>
</tr>
<tr>
<td>Sarah Walmsley</td>
<td>University of Edinburgh, UK</td>
</tr>
<tr>
<td>Ari Waisman</td>
<td>University of Mainz, DE</td>
</tr>
<tr>
<td>Corinela Weyand</td>
<td>Stanford University, US</td>
</tr>
<tr>
<td>Hao Wu, Milstein Award</td>
<td>Harvard University, US</td>
</tr>
</tbody>
</table>
MEETING VENUE AND LOCATION
Hofburg Conference Center
Heldenplatz, 1010 Vienna, Austria

MEETING ORGANIZER
MCI Suisse SA has been selected by ICIS as the official meeting organizer to process registrations, abstract management, exhibition and sponsorship. All correspondence should be sent to:

Cytokines 2019 c/o MCI Suisse SA
9 Rue de Pré-Bouvier
1242 Satigny, Geneva, Switzerland
E-mail: cytokines@mci-group.com

ICIS HEADQUARTERS
Joan Oefner, Managing Director
International Cytokine & Interferon Society
297 Kinderkamack Road, Suite 348
Oradell, NJ 07649, USA
Tel: +1 800 947 19 60 / +49 171 104 91 81
Fax: +1 201 322 18 18
E-mail: joefner@cytokinesociety.org
www.cytokinesociety.org

MEETING DOCUMENTS AND BADGES
Meeting documents should be collected on-site at the registration desk at the Hofburg Conference Center. Name badges must be worn visibly all times during the meeting and in the exhibition area.

MOBILE APPLICATION
Get all information you need at your fingertips with the Cytokines 2019 Mobile Application. It is available for free on iOS and Android.

CELLULAR PHONES AND PAGERS
As a courtesy to all meeting attendees and speakers, cellular phones and other electronic devices must be operated in silent or vibration mode during sessions. No cellular phone conversations are permitted during sessions. Picture taking, filming or recording of the sessions is forbidden.

CERTIFICATE OF ATTENDANCE
A certificate of attendance will be sent by email after the meeting to all duly registered participants who attended the meeting.

FOOD AND BEVERAGE
Complimentary coffee and tea are served in the exhibition during official coffee breaks. Lunch will be provided to the attendees of the lunchtime sessions only. For other delegates, there are several restaurants within walking distance of the Hofburg Conference Center. Please check the meeting app for details and directions.

INTERNET
Free wireless internet access is available in the meeting spaces.
WiFi Name: HofburgSecured
Password: Cytokines19

OFFICIAL LANGUAGE
The official meeting language is English. No simultaneous interpretation will be available.

SMOKING POLICY
The meeting venue is entirely non-smoking.

SURVEY/MEETING EVALUATION
We would be grateful if you can take a few minutes to answer an online survey that will be sent to you shortly after the meeting. Your valuable feedback will help us to improve the organization and quality of future Cytokines meetings.

REGISTRATION DESK OPENING HOURS
Sunday 20 October 15:00 - 20:30
Monday 21 October 08:00 - 17:30
Tuesday 22 October 08:00 - 17:30
Wednesday 23 October 08:00 - 15:00

EXHIBITION OPENING HOURS
Sunday 20 October 16:00 - 20:30
Monday 21 October 10:00 - 16:00
Tuesday 22 October 10:00 - 16:00
Wednesday 23 October 10:00 - 14:00

SPEAKERS’ PREVIEW ROOM OPENING HOURS
Sunday 20 October 15:00 - 18:00
Monday 21 October 08:00 - 17:30
Tuesday 22 October 08:00 - 17:30
Wednesday 23 October 08:00 - 15:00

TRAVEL INSURANCE
It is recommended that participants obtain adequate cover for travel, health and accident insurance before they depart from their countries. Cytokines 2019 and MCI Suisse S.A. as organizers cannot accept responsibility for personal injuries, or loss of, or damage to, private property belonging to the delegates and accompanying persons.

WEBSITE
www.vienna.cytokinesociety.org
Networking Events

SUNDAY 20 OCTOBER
19:25 - 20:30 - Welcome Reception - Hofburg Conference Center

The scientific organizing committee is pleased to welcome all participants and registered accompanying persons to renew connections and meet new colleagues.

Due to the central location of the Hofburg venue in the heart of Vienna, participants are encouraged to visit some of the nearby restaurants together in groups following the welcome reception. Please use the meeting app for more information.

TUESDAY 22 OCTOBER
19:15 - 23:00 - Networking Dinner - Rathaus, City Town Hall

The official meeting networking evening is a great opportunity for delegates to exchange and share knowledge in a more informal setting. The evening will be accompanied with music from the band Grossmütterchen Hatz & Klok, providing the perfect setting for the dance floor.

This will be a standing dinner to motivate networking and not a standard sit-down gala dinner.

Delegates who wish to attend this networking opportunity need to reserve for their ticket, in advance. For those that have not reserved a ticket please check at the registration desk as soon as possible for availability of additional tickets, which are at a price of € 50 for participants and € 25 for trainees.

The venue is provided with the kind support of the Vienna Mayor’s office.

GROSSMÜTTERCHEN HATZ & KLOK

The GROSSMÜTTERCHEN (means “Grandma”) HATZ & KLOK is a humorous “Worldjazzfolkskapop-Quintet”. Their influences are drawn from Klezmer, Balkan Folk, Latin American and from classical music. Their debut album “Gallato” was presented at the International Klezmore-Festival 2011.

Since spring 2016 they tour with a new 5 piece line up. Combine virtuoso musicians who have played with Randy Brecker, Dean Bowman and for Shantels Bucovina Club Orkestar or the Sandy Lopicic Orkestar amongst others, dance tunes and passion for playing … the audience loves this “cocktail”.

Rathaus
Hofburg Conference Center
Combining Caring with Research –

For a better Life

This is our challenge and ambition - and has been for the last 140 years. We have been constantly looking for new ways to improve people’s lives. This is why we develop new medicines for people with e.g. Rheumatoid Arthritis, so they can be treated even more effectively in the future.

More information at: www.lilly.at
## Program Overview

### Sunday 20 October

**Festsaal**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 17:00 - 19:25 | **Opening Ceremony**  
President’s Lecture  
Awards Ceremony  
2019 Milstein Award Winner Lectures  
Keynote Lecture |

**Poster & Exhibit Area**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:25 - 20:30</td>
<td><strong>Welcome Reception &amp; Opening of the Exhibition</strong></td>
</tr>
</tbody>
</table>

### Monday 21 October

**Festsaal**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 09:00 - 10:40 | **Plenary Session 1**  
Sponsored by BioLegend & Regeneron  
Mechanisms and treatment of skin inflammation: The IL-23/IL-17 pathway |

**Poster & Exhibit Area**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40 - 11:10</td>
<td><strong>Coffee Break &amp; Visit the Exhibition</strong></td>
</tr>
</tbody>
</table>

**Festsaal & Zeremoniensaal**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 11:10 - 12:55 | **Parallel Session 2**  
Sponsored by AstraZeneca  
Biology and targeting of type 2-mediated immune responses  
**Parallel Session 3**  
Sponsored by Nektar Therapeutics  
Induction of immune tolerance – fact or fiction? |
| 12:45 - 14:15 | **Break**                                                           |

**Festsaal & Zeremoniensaal**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 13:15 - 14:15 | **Oral Abstract Session 1**  
with a focus on cytokine signaling  
Presentations with lunch  
**Oral Abstract Session 2**  
with a focus on T cells  
Presentations with lunch |

**Poster Area**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15 - 15:50</td>
<td><strong>Poster Session 1</strong></td>
</tr>
</tbody>
</table>

**Festsaal & Zeremoniensaal**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 16:00 - 17:35 | **Parallel Session 4**  
Sponsored by Janssen  
Regulation of autoimmunity and autoimmune disease by cytokines  
**Parallel Session 5**  
Sponsored by Pfizer  
Cytokine biology meets the gut: Intestinal inflammation |
# Program Overview

**TUESDAY 22 OCTOBER**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 09:00 - 10:35 | **PLENARY SESSION 2**  
Sponsored by the Japanese Society of Interferon & Cytokine Research  
Cytokine-related diseases after checkpoint inhibition |
| 10:35 - 11:05 | **COFFEE BREAK & VISIT THE EXHIBITION**                                |
| 11:05 - 12:40 | **PARALLEL SESSION 7**  
Supported in part by an unrestricted educational grant from Cytokine Journal  
Immune metabolism regulating cytokine production and immune cell polarization  
**PARALLEL SESSION 8**  
Sponsored by Eli Lilly and Company  
Therapeutic targeting of the cytokine signaling pathways |
| 12:40 - 14:10 | **BREAK**                                                             |
| 13:10 - 14:10 | **ORAL ABSTRACT SESSION 3**  
with a focus on viral responses  
Presentations with lunch  
**ORAL ABSTRACT SESSION 4**  
with a focus on tumor responses  
Presentations with lunch |
| 14:10 - 15:40 | **POSTER SESSION 2**                                                  |
| 15:50 - 17:25 | **PARALLEL SESSION 9**  
Targeting neutrophils and macrophages in immune-mediated disease  
**PARALLEL SESSION 10**  
Orchestration of inflammatory responses by IL-6 |
<p>| 17:25 - 18:10 | <strong>ICIS MEMBERS MEETING AND DISTRIBUTION OF TRAVEL AWARDS</strong>            |
| 19:15 - 23:00 | <strong>NETWORKING DINNER AT THE VIENNA TOWN HALL</strong>                         |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Events</th>
</tr>
</thead>
</table>
| 09:00 - 10:45 | FESTSAAL       | **PARALLEL SESSION 11**  
Sponsored by Bristol-Myers Squibb  
Type I interferons: Biology and their role in disease |
|            | ZEREMONIENSAAL | **PARALLEL SESSION 12**  
Sponsored by Chugai Pharmaceutical  
Novel aspects of IL-6 inhibition in disease |
| 10:45 - 11:05 |               | **COFFEE BREAK & VISIT THE EXHIBITION**                                |
| 11:05 - 12:50 | FESTSAAL       | **PARALLEL SESSION 13**  
Sponsored by Novartis  
Cytokine-mediated resident tissue destruction and fibrotic responses |
|            | ZEREMONIENSAAL | **PARALLEL SESSION 14**  
Local and systemic effects of IL-1 family cytokines in disease |
| 12:50 - 14:00 |               | **BREAK**                                                              |
| 13:00 - 14:00 | FESTSAAL       | **ORAL ABSTRACT SESSION 5**  
with a focus on infection biology  
*Presentations with lunch* |
|            | ZEREMONIENSAAL | **ORAL ABSTRACT SESSION 6**  
with a focus on STING pathway  
*Presentations with lunch* |
| 14:00 - 15:35 |               | **PLENARY SESSION 3**  
The Mary Ann Liebert, Inc./Journal of Interferon and Cytokine Research Symposium in Honor of Philip I. Marcus:  
Pattern recognition receptors in immunity and disease |
| 15:35       |               | **CLOSING & INVITATION TO CYTOKINES 2020 IN SEATTLE**                   |
# Scientific Program - Sunday 20 October

### 17:00 - 17:05
**OPENING CEREMONY**

*Opening Remarks: Georg Schett (DE)*

### 17:05 - 17:35
**AWARDS CEREMONY**

*Presentation of the 2019 Milstein Awards, the 2019 BioLegend William E. Paul Award, ICIS Distinguished Services Award, the ICIS Honorary Lifetime Membership Award and the 2019 Young Investigator Awards
Bryan Williams (AU) & Kate Fitzgerald (US)*

**17:05 - 17:10**  
*Introduction: Nancy Reich (US)*

**17:05 - 17:35**  
*BioLegend William E. Paul Award: Chen Dong (CN) presented by Jie Zhou (US)*

*Honorary Lifetime Membership Award: Kouji Matsushima (JP)*

*Milstein Awards: Akiko Iwasaki (US) & Hao Wu (US)*

*Distinguished Services Award: Bryan Williams (AU)*

*Milstein Young Investigator Awards: Juan Luis Mendoza (US), Juan Fuxman Bass (US), Sarah Doyle (IE), Yuxin Wang (US), Ryan A. Langlois (US)*

*The Christina Fleischmann Award to Young Women Investigator: Meike Dittmann (US)*

*The Sidney Pestka Graduate Award & Post Graduate Award: Billur Akkaya (US), Anukriti Mathur (AU), presented by Robert Pestka (US)*

### 17:35 - 18:45
**2019 MILSTEIN AWARD WINNER LECTURES**

**17:35 - 18:05**  
*Milstein Award Lecture 1: Role of interferons in antiviral response: Akiko Iwasaki (US)*

**18:05 - 18:35**  
*Milstein Award Lecture 2: Inflammasomes in health and disease: Hao Wu (US)*

**18:35 - 18:45**  

### 18:45 - 19:25
**KEYNOTE LECTURE 1**

*Fueling the firestarters: Lydia Lynch (IE)*

### 19:25 - 20:30
**WELCOME RECEPTION & OPENING OF THE EXHIBITS**
11:00 - 12:00
PARALLEL SESSION 2: BIOLOGY AND TARGETING OF TYPE 2-MEDIATED IMMUNE RESPONSES

Inhibition of IL-17 and IL-23 as a treatment target in psoriasis: Diamant Thaci (DE)

A tale of two cytokines: IL-17 and IL-22 in fungal host defense: Sarah Gaffen (US)

IL-17 controls CNS autoimmunity through the intestinal microbiome: Ari Waismann (DE)

11:10 - 12:45
PARALLEL SESSION 3: INDUCTION OF IMMUNE TOLERANCE - FACT OR FICTION?

Type 2 immunity controls resolution of helminth-induced lung inflammation: David Voehringer (DE)

The role of TH2 cytokines in cutaneous immune responses: Kenji Kabashima (JP)

Pro-resolving and anti-inflammatory effects of TH2 immune responses in arthritis: Aline Bozec (DE)

O001 - Essential role of C-REL in IL-33-mediated activation of group 2 innate lymphoid cells: B. C. Mindt (CA)* - C. U. Duerr - M. Mancini - S. M. Vidal - P. Gros - D. Langlais - J. H. Fritz

O002 - Effective treatment of experimental asthma by lung-restricted inhibition of janus kinase 1: N. Ghilardi (US)*

Induction of immune tolerance – fact or fiction?: John Isaacs (UK)

Induction of immune tolerance in autoimmunity - what is standing in our way?: Jane H. Buckner (US)

Environmental sensors, innate immune regulation, and tolerance to self: Tracy L. McGaha (CA)

12:25 - 12:35
O003 - Engineering IL-10 super-agonists to boost IL-10 anti-inflammatory responses: I. M. Gonzalez (UK)* - C. Gorby - J. Sotolongo - J. Piehler


13:15 - 14:15
ORAL ABSTRACT SESSION 1: WITH A FOCUS ON T CELLS

Presentations with lunch
Sarah Gaffen (US) & Burkhard Becher (CH)

13:15 - 13:25
O005 - Interleukin-11 drives autoimmune pathologies through the induction of a unique CD4+ TH17 population: T. Putoczki (AU)* - K. Y. Fung - C. Louis - R. Metcalfe - I. Wicks - M. Griffin

13:25 - 13:35
O006 - Understanding the molecular signature and function of IL-22BP producing T cells: M. Sabihi (DE)* - P. Pelczar - S. Huber on behalf of AG Huber

13:35 - 13:45

13:45 - 13:55

13:55 - 14:05
O009 - Increased T cell polyreactivity with marked accumulation of TNF-A DP (CD4+CD8+) in the synovial tissue of pre-RA, arthralgia subjects: A. Floudas (IE)* - D. J. Veale - U. Fearon

14:05 - 14:15

14:15 - 15:00
POSTER SESSION 1

Refer to pages 26 - 31 for detailed program.
16:00 - 17:35  **FESTSAAL**  
**PARALLEL SESSION 4: REGULATION OF AUTOIMMUNITY AND AUTOIMMUNE DISEASE BY CYTOKINES**

Sponsored by Janssen  
Tracy McGaha (CA) & Yoshiya Tanala (JP)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:25</td>
<td>FESTSAAL</td>
<td>Role of innate like T cells in combined gut and joint inflammation</td>
<td>Dirk Elewaut (BE)</td>
</tr>
<tr>
<td>16:25 - 16:50</td>
<td>FESTSAAL</td>
<td>Environmental influences on intestinal stem cell physiology</td>
<td>Brigitta Stockinger (UK)</td>
</tr>
<tr>
<td>16:50 - 17:15</td>
<td>FESTSAAL</td>
<td>Innate immune cells drive intestinal tissue repair</td>
<td>Tom Cupedo (NL)</td>
</tr>
</tbody>
</table>

---

16:00 - 17:35  **GERMAN/ENGLISH INTERPRETATION**  

**PARALLEL SESSION 5: CYTOKINE BIOLOGY MEETS THE GUT: INTESTINAL INFLAMMATION**

Sponsored by Pfizer  
Cristina Bergamaschi (IT) & David Voehringer (DE)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:25</td>
<td>FESTSAAL</td>
<td>Role of the IL-23/Th17 axis on the B cell response</td>
<td>Gerhard Krönke (DE)</td>
</tr>
<tr>
<td>16:25 - 16:50</td>
<td>FESTSAAL</td>
<td>GM-CSF: T cell-phagocyte communication conduit</td>
<td>Burkhard Becher (CH)</td>
</tr>
<tr>
<td>16:50 - 17:15</td>
<td>ZEREMONIENSAAL</td>
<td>Neuronal-immune cell network regulates tissue response during inflammation</td>
<td>Francesca Barone (UK)</td>
</tr>
<tr>
<td>17:15 - 17:25</td>
<td>ZEREMONIENSAAL</td>
<td>O017 - NK cell-derived GM-CSF potentiates autoantibody-induced inflammatory arthritis and is negatively regulated by CIS: C. Louis (AU)* - F. S.-F. Guimaraes - N. Huntington - L. Wicks on behalf of the Walter and Eliza Hall Institute of Medical Research</td>
<td></td>
</tr>
<tr>
<td>17:25 - 17:35</td>
<td>ZEREMONIENSAAL</td>
<td>O018 - Multiomics: Low but differential expression of IFNγ has distinctive mechanistic features linking chronic inflammation to autoimmunity</td>
<td>H. Young (US)* - R. Bae - D. Hodge - J. Fenimore - V. Thovarai - A. Dzutsev - G. Trinchieri - M. E. Gershwin</td>
</tr>
</tbody>
</table>

---

16:00 - 17:35  **ZEREMONIENSAAL**  

**PARALLEL SESSION 5: CYTOKINE BIOLOGY MEETS THE GUT: INTESTINAL INFLAMMATION**

16:00 - 16:25  
The impact of the IL-23/Th17 axis on the B cell response: Gerhard Krönke (DE)

16:25 - 16:50  
GM-CSF: T cell-phagocyte communication conduit: Burkhard Becher (CH)

16:50 - 17:15  
Neuronal-immune cell network regulates tissue response during inflammation: Francesca Barone (UK)

17:15 - 17:25  
O017 - NK cell-derived GM-CSF potentiates autoantibody-induced inflammatory arthritis and is negatively regulated by CIS: C. Louis (AU)* - F. S.-F. Guimaraes - N. Huntington - L. Wicks on behalf of the Walter and Eliza Hall Institute of Medical Research

17:25 - 17:35  
O018 - Multiomics: Low but differential expression of IFNγ has distinctive mechanistic features linking chronic inflammation to autoimmunity: H. Young (US)* - R. Bae - D. Hodge - J. Fenimore - V. Thovarai - A. Dzutsev - G. Trinchieri - M. E. Gershwin
### Scientific Program - Tuesday 22 October

#### 09:00 - 10:35

**PLENARY SESSION 2: CYTOKINE-RELATED DISEASES AFTER CHECKPOINT INHIBITION**

**FESTSAAL**

**Sponsored by the Japanese Society of Interferon & Cytokine Research**

**Georg Schett (DE) & Brigitta Stockinger (UK)**

- **09:00 - 09:25**
  - TBA: Lucie Heinzerling (DE)

- **09:25 - 09:50**
  - Regulation of autoimmunity by PD-1 and LAG-3: Taku Okazaki (JP)

- **09:50 - 10:15**
  - Adverse events in pituitary and thyroid glands induced by immune checkpoint inhibitors: Shintaro Iwama (JP)

- **10:15 - 10:25**

- **10:25 - 10:35**

#### 10:35 - 11:05

**EXHIBIT AREA**

**COFFEE BREAK & VISIT OF THE EXHIBITION**

#### 11:05 - 12:40

**PARALLEL SESSION 7: IMMUNE METABOLISM REGULATING CYTOKINE PRODUCTION AND IMMUNE CELL POLARIZATION**

**FESTSAAL**

**Supported in part by an unrestricted educational grant from Cytokine Journal**

Dhan Kalvakolanu (US) & Gerhard Krönke (DE)

- **11:05 - 11:30**
  - Semaphorin 6D reverse signaling controls macrophage lipid metabolism and anti-inflammatory polarization: Atushi Kumanogo (JP)

- **11:30 - 11:55**
  - Bioenergetic strategies of pro-inflammatory T cells: Cornelia Weyand (US)

- **11:55 - 12:20**
  - Systemic immunometabolism in viral infection: Andreas Berghthaler (AT)

- **12:20 - 12:30**
  - O023B - 2-Hydroxyglutarate is a critical regulator of macrophage function: N. Williams (IE)* - D. Ryan - A. Costa - L. O’Neill

- **12:30 - 12:40**

#### 11:05 - 12:40

**PARALLEL SESSION 8: THERAPEUTIC TARGETING OF THE CYTOKINE SIGNALING PATHWAYS**

**ZEREMONIENSAAL**

**Supported by Eli Lilly and Company**

Cem Gabay (CH) & Yoshiya Tanaka (JP)

- **11:05 - 11:30**
  - Blocking only the bad side of Interleukin-6 in inflammation and cancer: Stefan Rose-John (DE)

- **11:30 - 11:55**
  - The ADAM17 protease triggers deregulated cytokine signaling and is a therapeutic target in lung diseases: Brendan Jenkins (AU)

- **11:55 - 12:20**
  - Therapeutic targeting of the cytokine signaling pathways: Peter Taylor (UK)

- **12:20 - 12:30**
  - O025 - The molecular basis of JAK/STAT inhibition by SOCS1: N. J. Kershaw (AU)* - N. P. Liu - N. A. Nicola - J. J. Babon

- **12:30 - 12:40**
Scientific Program - Tuesday 22 October

12:40 - 14:10
BREAK

13:10 - 13:20
0027 - Novel molecular inducers of CGAS-STING signaling exhibit diverse therapeutic and mechanistic impact: V. Defilippis (US)*

13:20 - 13:30

13:30 - 13:40
0029 - Aberrant STING signaling in COPA syndrome: A. Steiner (AU)* - S. Davidson - S. L. Masters

13:40 - 13:50
0030 - The intrinsic regulation of the STING-dependent type I interferon induction by the hepatic transmembrane serine protease, hepsin: H. M. Liu (TW)* - F. Hsin

13:50 - 14:00

14:00 - 14:10
0032 - Molecular and cellular dissection of STING-associated vasculopathy with onset in infancy (SAVI) mediated intestinal inflammation: L. Shmuel-Galia (US)* - F. Humphries - K. A. Fitzgerald

13:10 - 13:20

13:20 - 13:30
0034 - NF-KB and NFAT pathways shape mesenchymal stem cell response to PAMPS: F. Tidu (CZ)* - M. De Zuani - K. Benidckova - S. S. Jose - J. Fric

13:30 - 13:40
0035 - DAPK family members are negative regulators of RIG-I signaling: V. Goncalves Magalhaes (DE)* - J. Wolanski - J. Willemsen - M. Binder

13:40 - 13:50
0036 - STAT1 displays functionally distinct phosphorylation upon LPS stimulation: H. Metwally (JP)* - T. Kishimoto

13:50 - 14:00

14:00 - 14:10
0038 - Interleukin 6 trans-signaling controls liver regeneration after partial hepatectomy: J. Scheller (DE)* - N. Fazel Modares - R. Polz

14:10 - 15:40
POSTER SESSION 2

Refer to pages 34 - 39 for detailed program.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Venue</th>
<th>Speakers/Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:50 - 17:25</td>
<td>PARALLEL SESSION 9: TARGETING NEUTROPHILS AND MACROPHAGES IN IMMUNE-MEDIATED DISEASE</td>
<td>FESTSAAL</td>
<td>Scott Durum (US) &amp; Georg Schett (DE)</td>
</tr>
<tr>
<td>15:50 - 16:15</td>
<td>Transcriptional control of myeloid cells:</td>
<td></td>
<td>Irina Udalova (UK)</td>
</tr>
<tr>
<td>16:15 - 16:40</td>
<td>Fuelling neutrophilic inflammation:</td>
<td></td>
<td>Sarah Walmsley (UK)</td>
</tr>
<tr>
<td>16:40 - 17:05</td>
<td>Microbiota-neutrophil cross-talk in cancer therapy:</td>
<td></td>
<td>Romina Goldszmid (US)</td>
</tr>
<tr>
<td>17:25 - 18:10</td>
<td>ICIS MEMBERS MEETING AND DISTRIBUTION OF TRAVEL AWARDS</td>
<td>FESTSAAL</td>
<td></td>
</tr>
<tr>
<td>19:15 - 23:00</td>
<td>NETWORKING DINNER - Additional registration required</td>
<td>VIENNA TOWN HALL</td>
<td></td>
</tr>
</tbody>
</table>
Scientific Program - Wednesday 23 October

**PARALLEL SESSION 11: TYPE I INTERFERONS: BIOLOGY AND THEIR ROLE IN DISEASE**

- **FESTSAAL**
  - **09:00 - 10:45**
  - **09:00 - 09:25**
    - The epithelial IFN: IFN-kappa and its role in health and disease: Johann Gudjonsson (US)
  - **09:25 - 09:50**
    - Type I interferons in an expanding spectrum of autoimmune diseases: Raphaela Goldbach Mansky (US)
  - **09:50 - 10:15**
    - Cytokine interference in infection: Anne O’Garra (UK)
  - **10:15 - 10:25**
    - Milstein Young Investigator Award Winner Presentation: O043 - Phosphorylation of STAT2 on T404 is critical for interferon-mediated signaling and antiviral defense: Y. Wang (US) - X. Wang - C. Zhao - B. Willard - J. Yang - G. Stark
  - **10:25 - 10:35**
  - **10:35 - 10:45**

**PARALLEL SESSION 12: NOVEL ASPECTS OF IL-6 INHIBITION IN DISEASE**

- **ZEREMONIENSAAL**
  - **09:05 - 10:25**
    - An update on the pathogenic role of IL-6 in rheumatic diseases: Yuko Kaneko (JP)
    - IL-6 as a key mediator linking inflammation and structural bone changes in arthritis: Georg Schett (DE)
    - Cumulative and updated evidence of IL-6 signaling inhibition in RA: Tsutomu Takeuchi (JP)
    - Systemic effect of IL-6 blockade beyond the joints: Cem Gabay (CH)

**EXHIBIT AREA**

- **09:00 - 10:45**
  - PARALLEL SESSION 11: TYPE I INTERFERONS: BIOLOGY AND THEIR ROLE IN DISEASE
  - Anne O’Garra (UK) & Thomas Decker (AT)
  - PARALLEL SESSION 12: NOVEL ASPECTS OF IL-6 INHIBITION IN DISEASE
  - Georg Schett (DE) & Yoshiya Tanaka (JP)

- **10:45 - 11:05**
  - COFFEE BREAK & VISIT THE EXHIBITION
### PARALLEL SESSION 13: CYTOKINE-MEDIATED RESIDENT TISSUE DESTRUCTION AND FIBROTIC RESPONSES

**FESTSAAL**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:05 - 11:30</td>
<td>Interleukin-1: A key player in cerebrovascular disease: Stuart Allan (UK)</td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:55</td>
<td>Escalating inflammation: Stressed monocytes switch from vesicular to gasdermin D-mediated IL-1B secretion: Anna Rubartelli (IT)</td>
<td></td>
</tr>
<tr>
<td>11:55 - 12:20</td>
<td>The role of IL-1 family cytokines in vaccine adjuvanticity: Ed Lavelle (IE)</td>
<td></td>
</tr>
<tr>
<td>12:30 - 12:40</td>
<td>Interleukin-18 alters cellular organization in choroidal neovascular lesions: S. Doyle (IE)* - E. Ozaki - K. Brennan - E. Connolly - M. Campbell</td>
<td></td>
</tr>
</tbody>
</table>

### PARALLEL SESSION 14: LOCAL AND SYSTEMIC EFFECTS OF IL-1 FAMILY CYTOKINES IN DISEASE

**ZEREMONIENSAAL**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:05 - 11:30</td>
<td>Interleukin-1: A key player in cerebrovascular disease: Stuart Allan (UK)</td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:55</td>
<td>Escalating inflammation: Stressed monocytes switch from vesicular to gasdermin D-mediated IL-1B secretion: Anna Rubartelli (IT)</td>
<td></td>
</tr>
<tr>
<td>11:55 - 12:20</td>
<td>The role of IL-1 family cytokines in vaccine adjuvanticity: Ed Lavelle (IE)</td>
<td></td>
</tr>
<tr>
<td>12:30 - 12:40</td>
<td>Interleukin-18 alters cellular organization in choroidal neovascular lesions: S. Doyle (IE)* - E. Ozaki - K. Brennan - E. Connolly - M. Campbell</td>
<td></td>
</tr>
</tbody>
</table>

**BREAK**
**13:00 - 14:00**
**FESTSAAL**
**ORAL ABSTRACT SESSION 5: WITH A FOCUS ON INFECTION BIOLOGY**

Presentations with lunch
Kate Fitzgerald (US) & Howard Young (US)

**13:00 - 13:10**

**13:10 - 13:20**
**O050** - Immunosuppression by CX3CR1-dependent monocytes in cancers: A real-time intravital characterization: K. Jung (KR)* on behalf of Lab of Cancer Immunology and In Vivo Imaging

**13:20 - 13:30**

**13:30 - 13:40**
**O052** - Specific targeting of Type I interferon to the tumor microenvironment or to dendritic cells as a novel, generic and safe cancer immunotherapy: A. Cauwels (BE)* - S. Van Lint - A. Van Parys - F. Paul - G. Garcon - B. Vandekerckhove - N. Kley - G. Uze - J. Tavernier

**13:40 - 13:50**

**13:50 - 14:00**
**O054** - IL-15 deficient colon carcinomas have decreased cytolytic lymphocytes and skewed myeloid cell populations: K. S. Schluns (US)* - C.-C. Chou - R. M. Santana Carrero - S. M. Hegde
### Scientific Program - Wednesday 23 October

**PLENARY SESSION 3: PATTERN RECOGNITION RECEPTORS IN IMMUNITY AND DISEASE**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:40</td>
<td>Keynote Lecture 2: A new look at interferon signaling: Thomas Decker (AT)</td>
</tr>
<tr>
<td>14:40 - 15:05</td>
<td>C-type lectins: Unrecognised master regulators of immunity: Gordon Brown (UK)</td>
</tr>
<tr>
<td>15:05 - 15:30</td>
<td>Context dependent action of STAT3 in KRAS oncogenesis: Nancy Reich (US)</td>
</tr>
<tr>
<td>15:30 - 15:35</td>
<td>Invitation to Cytokines 2020 in Seattle</td>
</tr>
</tbody>
</table>

---

**SAVE THE DATE**

8th Annual Meeting of the International Cytokine & Interferon Society

1 - 4 November

Hyatt Regency Seattle, USA

Structure-Function & Systems Biology of Cytokines

www.seattle.cytokinesociety.org
Antibodies Recognize Antigens...

How will you get **recognized** for your immunology research?

*Science Immunology* publishes original, peer-reviewed, science-based research articles that report critical advances in all areas of immunological research, including important new tools and techniques.

Submit your research today. Learn more at: [SciencelImmunology.org](http://SciencelImmunology.org)

@ScienceImmunology  @scilImmunology
An Editorial Process Guided by Your Community

At JEM, all editorial decisions on research manuscripts are made through collaborative consultation between professional scientific editors and the academic editorial board.

1. Submission or transfer
2. Academic and scientific editors review
3. If appropriate, sent to Peer Review
4. Academic and scientific editors review comments
5. Informed discussions sent to authors
6. Revised manuscript submission and review
7. Academic and scientific editors review
8. 95% of invited revisions accepted
9. Published online 4-6 days after author proofs returned
10. Circulated via clients and social media to readers around the world
ANTI-CYTOKINE THERAPY

Highlighted posters will part of a poster tour chaired by Stefan Rose-John (DE)

**P001 - MONOBODY APPROACH TO TARGET THE DARK SIDE OF INTERLEUKIN-22 SIGNALING / C. Michiels* - G. La Sala - O. Hantschel - L. Dumoutier**


**P003 - MODULATION OF THE IL-6 SIGNALING PATHWAY IN LIVER CELLS BY MIRNAS TARGETING GP130, JAK1 AND/OR STAT3 / I. Behrmann* - F. A. Servais - M. Kirchmeyer - M. Hamdorf - N. W. Minoungou - S. Rose-John - S. Kreis - C. Haan**


**P006 - USING PARTIAL LEAST SQUARES REGRESSION ANALYSIS OF SERUM CYTOKINE AND CHEMOKINE PATTERNS TO CLASSIFY CASTLEMAN’S DISEASE AND RHEUMATOID ARTHRITIS / K. Uno* - K. Yoshizaki - M. Tanigawa - H. Fujimiya**

**P007 - CYCLO (VAL-PRO) ATTENUATES RENAL INJURY BY INHIBITING PRO-INFLAMMATORY CYTOKINES IN MICE RENAL ISCHEMIC MODEL / K. Hira* on behalf of A. Sajeli Begum**

**P008 - DISSECTING THE CYTOKINE HIERARCHY DRIVING DISEASE IN A MOUSE MODEL OF THE CYTOKINE RELEASE SYNDROME I / L. Nouveau* - L. Cons - L. Chatel - W. Ferlin**

**P009 - INTERLEUKIN-2 TREATMENT INHIBITS FOLLICULAR CYTOTOXIC CD8 T CELLS AND DETERIORATES CD8 T CELL-MEDIATED IMMUNOPATHOLOGY DURING VIRAL INFECTION / P. Zhou* - D. Yu**

**P010 - CYTOKINES INHIBITION EFFECT OF STANDARDIZED EXTRACT OF AN ENDOPHYTIC FUNGI FROM PIPER NIGRUM L / P. P. Pal* - A. S. Begum**

**P011 - TARGETING PROLONGED STAT3 ACTIVATION IN GBM CANCER STEM CELLS I / S. Wightman* - Y. Wang - T. Alban - J. Latvia - G. Stark**


**P014 - SMALL-MOLECULE INHIBITORS OF PRO-INFLAMMATORY CYTOKINES (TNF-A, IL-6 AND IL-1B) EFFECTIVE UNDER LPS-INDUCED MOUSE ENDOTOXEMIA MODEL / S. B. Ahtila* - S. K. S - K. Hira**

**P015 - DISSECTING THE CYTOKINE HIERARCHY DRIVING DISEASE IN A MOUSE MODEL OF THE CYTOKINE RELEASE SYNDROME / L. O’Neill**

**P016 - TARGETING P38MAPK FOR THE TREATMENT OF AUTOINFLAMMATORY DISEASES / S. E. Corcoran**

**P017 - MODULATION OF CYTOKINE ACTIVITY BY TETRACYCLINE AND DOXYCYCLINE ALTERS DISEASE COURSE IN EXPERIMENTAL EBOLA, MARBURG AND LASSA VIRUS INFECTIONS / T. M. Fredeking**

**P018 - MODULATION OF CYTOKINE ACTIVITY BY TETRACYCLINE AND DOXYCYCLINE ALTERS DISEASE COURSE IN EXPERIMENTAL EBOLA, MARBURG AND LASSA VIRUS INFECTIONS / T. M. Fredeking* - G. Ignatyev - A. Atrasheuskaya**

**P019B - MITOGEN-ACTIVATED PROTEIN KINASE ACTIVATING PEPTIDE, AES-16-2M PROMOTES ITGB1 THROUGH WOUND HEALING IN HUMAN DERMAL FIBROBLASTS / H. Kim**

**P019C - MITOGEN-ACTIVATED PROTEIN KINASE ACTIVATING PEPTIDE, AES-16-2M PROMOTES ITGB1 THROUGH WOUND HEALING IN HUMAN DERMAL FIBROBLASTS / H. Kim* - Y. Yang - S.-I. Bang**

**P019D - MICROWAVE PLASMA ENHANCES WOUND HEALING EFFECTS BY THE RELEASE OF NITRIC OXIDE AND INDUCTION OF ERK PATHWAY / M. Jeon - Y. Yang - S.-I. Bang**

**P019E - EVALUATION OF THE ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITY OF ANCHOMANES DIFFORMIS IN A DIABETIC ANIMAL MODEL / O. Oguntibeju**

**AUTOINFLAMMATION AND AUTOIMMUNITY**

Highlighted posters will part of a poster tour chaired by Tracy L. McGaha (CA)

**P020 - B AND T CELL PHENOTYPE AND FUNCTION IN THE SYNOVIAL TISSUE OF ACPA+ AND ACPA- RHEUMATOID ARTHRITIS PATIENTS / A. Floudas* - C. Low - M. Biniccka - D. J. Veale - U. Fearon**

**P022 - MACROPHAGE-DERIVED HIV-1 CARRIES BIOACTIVE TGF-BETA / A. Arakelyan* - J. Petersen - L. Margolis**


**P024 - INHIBITION OF IRF5 HYPER-ACTIVATION PROTECTS FROM LUPUS ONSET AND SEVERITY / S. Song - S. De - S. Sun - M. He - Y. Al-Abed - C. Aranow - M. Mackay - W. Clapp - B. Barnes**


P040 - ESSENTIAL ROLE OF IL-17A IN TREGS INDUCTION IN AUTOIMMUNE UAEITIS / W. P. Chong* - Y. Zhong - M. J. Mattapallil - J. Chen - R. R. Caspi


P043 - EXPRESSION OF PROINFLAMMATORY CYTOKINES IS REGULATED BY C-ABL-PARP1-P65 (RELA) SIGNALING PATHWAY / A. A. Bohio* - R. Wang - R. K. Sah - Y. Ke - X. Ba

P044 - POST-TRANSLATIONAL REGULATION OF STAT1 TYR701 PHOSPHORYLATION: SUMOYLATION VS. ADP-RIBOSYLATION / A. Begitt* - S. C. Krause - M. Dreescher - J. Vinkemeier

P045 - SERTOLI CELLS SUPPRESS TNF-ALPHA AND ENHANCE IL-10 PRODUCTION IN HEART AFTER MYOCARDIAL INFARCTION IN MICE / I. B. Porubská* - M. Hájková - M. Krulová


P048 - REGULATION OF K63 UBQUITIN SIGNALING BY THE INNATE IMMUNE SENSOR LGP2 / C. M. Horvath*

P049 - LOSS OF HEPATIC MACROPHAGE RESERVOIR DUE TO DECREASED CSF1 PRODUCTION MIGHT BE RESPONSIBLE FOR COMPROMISED RESOLUTION OF DAMAGE AND INCREASED SCARRING IN CHRONIC LIVER INJURY / D. Kumar* - S. Subham - A. Kumar

P051 - IL-36 CYTOKINES AS MEDIATORS OF VASCULAR FUNCTION / E. Fahey* - S. L. Doyle

P052 - BIOLOGY AND CHARACTERIZATION OF COVALENTLY LINKED INTERLEUKIN-10 / F. O. Minshawi* - W. Muller

P053 - AGE-RELATED CHANGES OF ADIPOCYTOKINES AND INTERLEUKINS IN HEALTHY INDIVIDUALS / I. Pantsulaia* - T. Atamashvili - M. Jgarkava - G. Devidze

P054 - DIFFERENTIAL IL-2RB ORGANIZATION IN B CELLS / F. O. Minshawi* - W. Muller

P059 - DEFINING AND ENGINEERING THE MOLECULAR BASIS OF INTERLEUKIN 12 FAMILY CYTOKINE BIOGENESIS / M. J. Feige*


P063 - ROLE OF CYTOKINES IN EXPERIMENTAL HEMORRHAGE TREATED WITH BLUMEA LACERA (BURM.F.) DC. LEAVES (EBL) IN RATS / S. Hemalatha* - T. Dubey - K. Bhanukiran


P066 - CYTOKINE EXPRESSION IN THE TEAR FLUIDS OF DIABETIC PATIENTS IN THE PRESENCE AND ABSENCE OF DRY EYE DISEASE / S. Hagan* - A. S. Konstantinou - M. Byambajav

P067 - INDUCTION OF ONCOSTATIN M EXPRESSION BY ACUTE EXERCISE IN THE SKELETAL MUSCLES AND SERA OF MICE / T. Komori* - Y. Morikawa

P069 - THE INTERPLAY OF CYTOKINE RESPONSE AND CYTOMEGALOVIRUS DYNAMICS / U. Rand* - T. Kubsch - B. Kasmapour - L. Clein-Sain

P070 - FUNCTIONAL ROLES OF ONCOSTATIN M IN THE PATHOGENESIS OF NONALCOHOLIC STEATOHEPATITIS IN MICE / Y. Morikawa* - I. Komori


P070C - 3-D CHROMATIN INTERACTOME AND CYTOKINE-MEDIATED TRANSCRIPTIONAL REGULATION IN PRIMARY HUMAN T CELLS / P. Li* - W. J. Leonard


P070E - CYTOKINE BLOOD PLASMA PROFILE OF PREMATURE NEWBORNS AFTER THERAPY WITH IFN ALPHA-2B AS A PART OF A COMBINED CONGENITAL PNEUMONIA THERAPY / A. Shuvalov*
P089 - TRANSCRIPTIONAL REGULATION OF CYTOKINE INDUCTION BY PYHIN PROTEINS / M. Baran* - P. Slivka

P091 - STAT3 COOPERATES WITH PHOSPHOLIPID SCRAMBLASE 2 TO SUPPRESS TYPE I INTERFERON-INDUCED ANTIVIRAL AND INFLAMMATORY RESPONSE / M. H. Tsai* - C. K. Lee


P093 - 2-HYDROXYGLUTARATE IS A CRITICAL REGULATOR OF MACROPHAGE FUNCTION / N. Williams* - D. Ryan - A. Costa - L. O’Neill

P094 - ALVEOLAR MACROPHAGES SENSITIZED TO OXIDANTS AND LUNG VOLUMES OF THE INFLAMED LUNGS OF COPD AND SARCOIDOSIS PATIENTS / P. Jacobsson* - L. Vainikka - H. L. Persson


P096 - INTERFERON-EPSILON IS A UNIQUE TYPE-I IFN PREDOMINANTLY EXPRESSED IN THE FEMALE REPRODUCTIVE TRACT THAT SUP-PRESSES ZIKV REPLICATION AND INTRAVINULAR TRANSMISSION / R. C. Coldbeck-Shackley* - M. Tate - P. Hertzog - N. Eyre - K. Van der Hoek - M. Beard

P097 - HIGH-RESOLUTION KINETIC CHARACTERIZATION OF THE RIG-I SIGNALING PATHWAY AND THE ENSUING ANTIVIRAL RESPONSES / S. Niesik* - D. Schweinoch - M. Binder

P098 - GLOBAL 3’-UTR LENGTH CHANGES MEDIATED BY INTERFERON BETA IN MURINE AN HUMAN MACROPHAGES / S. Straub* - L. J. Gearing - S. C. Forster - M. Baran* - P. Slivka


P100 - TYPE-I IFN-DEPENDENT CONCERTED RECRUITMENT OF MONOCYTES AND NK CELLS DURING MUCOSAL INFECTION WITH HERPES VIRUS / J. S. K. Eto* - E. Uyangaa - J. Y. Choi - S. O. Park


P103 - ZNF598 DELIVERS A UBIQUITIN-LIKE MODIFIER FAT10 TO RIG-I AND ATTENUATES THE INNATE IMMUNE RESPONSE AGAINST VIRAL INFECTION / T. Kouwaki* - H. Oshiumi

P104 - HYPOXIA INDUCES ENHANCEMENT OF INFLAMMASOME ACTIVATION BY P. GINGIVALIS INFECTION / T. Okano* - T. Suzuki

P105 - CHARACTERISING NEW INTERFERON: RECEPTOR INTERACTIONS AND THEIR IMPACT ON SIGNALING DIVERSITY / U.-S. Huang* - N. de Weerd - E. de Geus - N. Mangan - J. Volanic - P. Hertzog


P110 - REGULATION OF NON-CANONICAL INFLAMMASOME ACTIVATION BY XIAP / Y. H. Wu* - S. T. Mo - M. Z. Lai

P110A - DUSP4 REGULATES STING- AND RIG-I MEDIATED SIGNALLING IN RESPONSE TO VIRAL INFECTION / Y. Zhang* - S. J. James

P110B - ZIKA VIRUS NS5 PROTEIN AND INNATE IMMUNITY / M. T. Sanchez-Aparicio* - A. Garcia-Sastre


MUSOCAL IMMUNITY
Highlighted posters will part of a poster tour chaired by Mariana Kaplan (US)

P111 - BERBERIS LYCIIUM FRUIT EXTRACT MAINTAINS INTESTINAL HOMEOSTASIS IN DEXTRAN SULPHATE SODIUM INDUCED COLITIS BY MITIGATING NF-KB/C-JUN/MAPKS SIGNALING CASCADE AND ENHANCING TREGS IN SPLENIC LYMPHOCYTES / A. Sharma* - N. V. Tirpude - R. Sharma - Y. S. Padwad

P112 - MICROBIOTA-DRIVEN TONIC INTERFERON SIGNALS IN LUNG StromAL CELLS PROTECT FROM INFLUENZA VIRUS INFECTION / J. A. Wack*

P113 - CONTEXT-DEPENDENT REGULATION OF MRNA DECAY AND ITS FUNCTIONAL CONSEQUENCES / A. Bestehorn* - F. Ebner - P. Kovarik


P117 - GEF-H1 IS ESSENTIAL FOR INTESTINAL ANTI-VIRAL IMMUNITY BY REGULATING INTERFERON-LAMBDA EXPRESSION / Y.-C. Peng - Y.-C. Chen - F. Hsin - H.-S. Chang*

P119 - EFFECT OF ANTIBIOTIC-INDUCED CHANGES IN MICROBIOTA ON REGULATORY T CELLS IN MUC2−/−MICE / K. Achasova* - E. Kozhevnikova - M. Borosova - E. Litvinova

P121 - IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ABCF1 IN HUMAN AIRWAY EPITHELIAL CELLS IN RESPONSE TO VIRAL STIMULI / G. T. Cao* - N. Abbas - J. Aguilar - A. Doxey - K. Ask - J. A. Hirota


P124 - FUNCTIONAL MODELING OF THE RARE HUMAN DISEASE DITRA UNVEILS NOVEL ROLE OF IL-36R AXIS IN INTESTINAL INFLAMMATION / S. Haxhinasto* - Z. Hovhannisyan on behalf of Regeneron Pharmaceuticals


P125A - CD103HI T CELLS REGULATE LUNG FIBROTIC RESPONSE INDUCED BY CD103LO TISSUE-RESIDENT PATHOGENIC CD4 T CELLS / K. Hirahara* - T. Ichikawa - K. Kokubo - T. Nakayama


P125C - DIFFERENTIAL CYTOKINE EFFECTS ON INTESTINAL STROMAL CELLS UNDERLIE PATHOGENIC TISSUE SIGNATURES IN INFLAMMATORY BOWEL DISEASE / M. Friedrich* - M. Pohin - M. Jackson - S. Bullers - Z. Christoforidou - K. Rue-Albrecht - S. Sansom - F. Powne

P125D - IL-17A/F1 DEFICIENCY DWON-REGULATES IMMUNE-RELATED GENE EXPRESSION AND CHANGES TO INTESTINAL FLORA IN JAPANESE MEDAKA (ORYZIAS LATIPES) / I. M. Sakai* - Y. Okamura - N. Morimoto - T. Kono - J.-I. Hikima


T CELL DIFFERENTIATION AND FUNCTION


P132 - IDENTIFICATION OF IMMUNOMETABOLITES THAT SHAPE THE ADAPTIVE ANTIVIRAL IMMUNE RESPONSE / J.-W. Genger* - A. Bergthaler

P133 - PROTOCOLS FOR IN VITRO ACTIVATION, POLARIZATION AND EVALUATION OF CD4+ T CELL LINEAGES / C. Dy - D. Yu - H. Sato - J. Love - B. Sun - S. Ji - W. Jiang - J. Zhou*


P135 - ANTIBODIES TARGETING THREE DIFFERENT DOMAINS OF S PROTEIN EXHIBIT HIGHLY POTENT NEUTRALIZING ABILITY AGAINST PSEUDOTYPED MERS-COV / J. Kim* - Y.-S. Choi


Highlighted posters will part of a poster tour chaired by Ari Waisman (DE)
P143 - ENDOGENOUS N-3 POLYUNSATURATED FATTY ACIDS ARE BENEFICIAL TO DAMPEN INFLAMMATORY RESPONSE MEDIATED BY CD8+ T CELLS AGAINST THE VIRAL INFECTION / S.-M. Lee* - Y.-J. Seo - K.-W. Kang - S. Kim - Y.-B. Cho

P144 - SPECIFIC TARGETING OF IL-1B ACTIVITY TO CD8+ T CELLS MOUNTS A STRONG CELLULAR ANTIGEN-SPECIFIC IMMUNE RESPONSE AND COMPLETELY PROTECTS AGAINST INFLUENZA INFECTION IN MICE / B. Van Den Eeckhout - L. Van Hoecke - E. Burg - S. Van Lint - F. Peelman - X. Saelens - J. Tavernier - S. Gerlo*


P145B - T CELL INTRINSIC NLRP3-INFLAMMASOME ACTIVATION PROMOTES HUMAN TH17 CELL PATHOGENICITY THROUGH IL-1A BUT NOT IL-1B PRODUCTION / C. Zielinski* - Y.-Y. Chao

P145C - ELUCIDATING THE MECHANISM OF AITL ONCOGENESIS BY ANALYZING CHARACTERISTICS OF INTRATUMORAL FOLLICULAR HELPER T CELLS / K. C. Han* - Y. S. Choi


P145E - DYNAMIC PROTEIN LANDSCAPE DURING INITIATION OF HUMAN TH17 CELL DIFFERENTIATION / S. K. Tripathi*

P145F - THE ROLE OF IL-1R SIGNALING IN DIFFERENTIATION AND FUNCTION OF TH17 CELLS / W. Miller-Little* - X. Li
ANNUAL AWARDS

NOMINATION/SUBMISSION DEADLINES:
• 5 March 2020: The Milstein Award and the ICIS-BioLegend William E. Paul Award
• 17 April 2020: Honorary Lifetime Membership & Distinguished Service Awards
• 15 May 2020: All Young Investigator Awards
• 1 June 2020: Milstein Travel Awards

More information/submission site: https://cytokinesociety.org/awards/

Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research
The preeminent Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research, commonly known as The Milstein Award, recognizes individuals who have made exceptional contributions to interferon and cytokine research, either in a basic or applied field. Many of these achievements have led to the advancement of human health. **Award:** $10,000 from the Milstein Family Grant. ICIS Crystal and travel reimbursement from ICIS as well as meeting registration waived for the year of the Award. Oral presentation at the Annual Meeting of the International Cytokine & Interferon Society, Cytokines 2020, 1-4 November in Seattle, USA. [www.seattle.cytokinesociety.org](http://www.seattle.cytokinesociety.org).

The Milstein family also supports The Milstein Young Investigator Awards and The Milstein Travel Awards for ICIS members presenting abstracts at Cytokines 2020.

ICIS BioLegend William E. Paul Award
This prestigious award is given to an investigator that has made significant contributions to cytokine and interferon research throughout their career. Through the generosity of BioLegend the award consists of $2500, ICIS Crystal (3 D structure of IL-4), travel reimbursement and meeting registration waived for the year of the Award. Oral presentation at Cytokines 2020.

The Sidney & Joan Pestka Graduate & Post-Graduate Awards for Excellence in Interferon and Cytokine Research
These awards are targeted to graduate students and post-doctoral fellows who have begun to make an impact in interferon and cytokine research. The Awards are designed to fill the gap among the awards currently offered by the ICIS to more senior investigators. Candidates must be actively working in interferon/cytokine research. Each award includes a $3500 cash award, $1500 travel grant to attend Cytokines 2020, a $2500 PBL Assay Science product credit for each awardee, and a complimentary one-year ICIS membership.

The Christina Fleischmann Award to Young Women Investigators
This award is open to young women investigators working in the cytokine, chemokine and interferon biology, thanks to the generosity of the Fleischmann Foundation in memory of outstanding interferon research scientist Christina Fleischmann. The award includes a $2000 cash award through a grant from the Fleischmann Family Fund.

Other ICIS Awards
• Honorary Lifetime Membership Award
• Distinguished Service Award
• Milstein Travel Awards
• Milstein Young Investigator Awards
The Seymour & Vivian Milstein Award
for Excellence in Interferon & Cytokine Research

Akkiko Iwasaki, Ph.D.
Waldemar von Zedtwitz Professor of Immunobiology, Molecular, Cellular and Developmental Biology, and Dermatology; Investigator, Howard Hughes Medical Institute, Yale University, New Haven, USA

Hao Wu, Ph.D.
Asa and Patricia Springer Professor of Structural Biology, Department of Biomedical Chemistry and Molecular Pharmacology, Harvard Medical School, and Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, USA

Chen Dong, Ph.D.
Professor and Director of the Institute for Immunology and Dean of the School of Medicine, Tsinghua University, Beijing, China

Kouji Matsushima, MD, Ph.D.
Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan

ICIS-BioLegend
William E. Paul Award
for Excellence in Cytokine Research

ICIS Honorary
Lifetime Membership Award

ICIS Distinguished
Service Award

The Sidney & Joan Pestka Graduate & Post Graduate Awards for Excellence in Interferon and Cytokine Research – sponsored by PBL Assay Science

Meike Dittmann, Ph.D.
Assistant Professor Department of Microbiology New York University School of Medicine, New York, NY, USA

Billur Akkaya, MD, D.Phil
Research Fellow, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA

Anukriti Mathur
PhD candidate, Department of Immunology and Infectious Disease, The John Curtin School of Medical Research, Australian National University, Canberra, Australia

The Christina Fleischmann Award to Young Women Investigators

Meike Dittmann, Ph.D.
Assistant Professor Department of Microbiology New York University School of Medicine, New York, NY, USA

Anukriti Mathur
PhD candidate, Department of Immunology and Infectious Disease, The John Curtin School of Medical Research, Australian National University, Canberra, Australia
AUTOINFLAMMATION AND AUTOIMMUNITY

Highlighted posters will part of a poster tour chaired by Georg Schett (DE)

P146 - HYPOXIA RESISTANT PATHOGENIC B CELLS ACCUMULATE IN THE RA SYNOVIAL TISSUE IN A CXCR3 DEPENDENT MANNER / A. Floudas* - C. Low - M. Binnieck - D. J. Veale - U. Fearon

P147 - INDUCIBLE MALT1 PROTEASE-DEFICIENT MICE: A MOUSE MODEL TO STUDY THE SAFETY OF MALT1 PROTEASE INHIBITION / A. Demeyer* - Y. Driege - J. Staal - R. Beyaert

P148 IL-17 DRIVES THE RECRUITMENT OF IL-1B-PRODUCING INNATE CELLS THAT PROMOTE THE DEVELOPMENT OF IL-17-SECRETING γδ T CELLS AND TH17 CELLS IN CENTRAL NERVOUS SYSTEM AUTOIMMUNITY / A. Mc Ginley* - C. Sutton - S. Edwards - K. Mills

P149 - IRF5 GENETIC RISK VARIANTS DRIVE MYELOID-SPECIFIC IRF5 HYPER-ACTIVATION AND PRE-SYMPOMATIC SLE / D. Li - B. Matta - S. Song - B. Barnes*

P150 - ACCUMULATIVE DEFECTS IN IRF5 KNOCKOUT B AND T CELLS CONTRIBUTE TO THE DEFECTIVE GENERATION OF ANTIBODY SECRETING CELLS / B. Matta* - Q. Guo - B. Barnes


P155 - CUTANEOUS AND SYNOVIO-ENTHESAL INFLAMMATION IN A NOVEL MODEL OF PSORIATIC ARTHRITIS / K. L. Yang*


P158-RELATIONSHIP BETWEEN FECALCALPROTECTIN AND INFLAMMATION IN PERIPHERAL JOINTS AND ENTHESES IN AXIAL SPONDYLOARTHRITIS / K. Y. Kang* - Y. S. Hong


P165A - TWO COMMON DISEASE-ASSOCIATED TYK2 VARIANTS IMPACT EXON SPlicing AND TYK2 DOSAGE / Z. Li* - M. Rotival - E. Patin - F. Michel - S. Pellegrini

P165B - TREM-2 MEDIATES MSU-INDUCED NALP3 INFLAMMASOME ACTIVATION AND IL-1 Beta INDUCTION THROUGH A PKC DELTA-DEPENDENT SIGNALING / N.-J. Chen*


CYTOKINE REGULATION

Highlighted posters will part of a poster tour chaired by Stefan Rose-John (DE)


P167 - RECONSTITUTING THE HUMAN JAK/STAT PATHWAY INTO DROSOPHILA S2 CELLS / A. L. McFarlane* - I. Moraga-Gonzalez


P167 - RECONSTITUTING THE HUMAN JAK/STAT PATHWAY INTO DROSOPHILA S2 CELLS / A. L. McFarlane* - I. Moraga-Gonzalez


P169 - IFN-BETA THERAPY IN MULTIPLE SCLEROSIS CHANGES THE RESPONSES TO IL-6, IL-10, AND IFN-GAMMA DIFFERENTLY IN CD4+ T CELLS AND ANTIGEN PRESENTING CELLS OF GOOD AND POOR ANTIEN PRESENTING CELLS / A. Landrigan - J. Killestein - R. Fox - G. R. Stark - A. H. H. Van Boxel-Dezaire

P171 - ONCOSTATIN M MODULATES WNT SIGNALING IN THE LUNGS OF C57BL/6 MICE / F. Botelho - A. Dvorkin - D. Bridgewater - C. D. Richards*

P172 - CRANIOSYNOSTOSIS-ASSOCIATED IL11RA MUTATIONS HAVE DIVERGENT EFFECTS ON THE INTERLEUKIN-11 RECEPTOR / C. Garbers* - M. Agthe - B. Kespoli - J. Lokau


P174 - CLOCK DEPENDENT IL1B AUTO-REGULATORY LOOP REGULATES INFLAMMATION IN GLIOMA / E. Sen* - P. Gowda - K. Lathoria - S. Sharma

P175 - DETERMINING THE ROLE OF MICROGLIA AND ASTROCYTES IN CEREBRAL TYPE 1 INTERFERONOPATHIES / E. Hayashida* - B. Vmiengkhoo - M. J. Hofer


P177 - CYTOKINE-SENSING ENHANCERS LAUNCH SECONDARY ENHANCERS TO ACTIVATE MULTI-GENE LOCUS / H. K. Lee* - L. Henninghausen

P178 - A20 IN MYELOID CELLS REGULATES IL-33-INDUCED LUNG INFLAMMATION / I. Afonina* - A. Hoilado - M. Haegman - R. Beyaert


P180 - DETERMINANTS OF IL-11 RECEPTOR PROTEOLYSIS / I. Lokau* - L. Koch - M. Agthe - C. Garbers

P181 - PHYSIOLOGY AND MECHANISM OF INTERLEUKIN-1 SIGNALING REGULATION BY TRISTETRAPROLIN / I. Sneezum* - P. Kovarik


P184 - GM-CSF- AND IRF4-DEPENDENT SIGNALING IN MACROPHAGES ELEVATES CCL17 PRODUCTION REQUIRED FOR ZYMOSAN-INDUCED ARTHRITIS / M. C. Lee* - A. Fleetwood - A. Achuthan - J. Hamilton - A. Cook


P190 - INTERLEUKIN-17D PROMOTES PATHOGENICITY DURING INFECTION BY SUPPRESSING CD8 T CELL ACTIVITY / S. H. Chang* - Y. Lee - J. Clinton - C. Yao


CYTOKINES IN ALLERGY AND TH2 IMMUNITY

P195 - EFFECT OF IL-33 TARGETING IN A. ALTERNATA-INDUCED ALLERGIC AIRWAY INFLAMMATION USING A NEWLY DEVELOPED IL-33 ANTAGONIST / A. Holgado* - R. Beyaert - I. Afonina - H. Braun


P204 - INVESTIGATION ON THE PATHOGENESIS OF PULMONARY COMORBIDITY ACCOMPANIED BY BOTH CHRONIC DISEASES, ASTHMA AND NONTUBERCULOUS MYCOBACTERIAL INFECTION, IN A MURINE MODEL / Y. Bak* - S. C. Park - D. Shim - Y. Ha - S. J. Shin

P204A - DETERMINATION OF INTERFERONS AND BIOMARKERS IN INFLUENZA DONOR SAMPLES / B. Schwartz - G. Koisel - A. Panady - K. Skup - W. Clark - T. Lavoie*

P204C - THERAPEUTIC EFFECT OF TOPICAL ADMINISTRATION OF RED ONION EXTRACT IN A MURINE MODEL OF ALLERGIC RHINITIS / M. Y. Seo* - H. Y. Kim

CYTOKINES IN CANCER DEVELOPMENT AND ANTITUMOR IMMUNE THERAPY
Highlighted posters will part of a poster tour chaired by Brendan Jenkins (AU)


P206 - ENGINEERING IL-12 TO ACHIEVE COMPLETE REMISSION IN ESTABLISHED, COLD TUMORS / A. Mansurov* - J. Ishihara - J. A. Hubbell


P208 - ASPIRIN MODIFIES OBESITY-RELATED METABOLIC PROFILES AND SUPPRESSES BREAST CANCER CELL GROWTH / C.-C. Hsieh* - C.-H. Wang


P216 - THE MULTI-SITE DOCKING PROTEIN GAB1 AND ITS ROLE IN BREAST CANCER / H. Bongartz* - F. Schaper


P219 - CXCL13 PLASMA LEVELS FUNCTION AS A BIOMARKER FOR DISEASE ACTIVITY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA / J. Burger* - M. Sivina


P222 - STAT5A AND STAT5B IN HEMATOPOIETIC AND LEUKEMIC STEM CELLS – BETWEEN DEATH AND IMMORTALITY / S. Kollmann* - M. Prchal-Murphy - B. Maurer - M. Farlik - V. Sexl


P226 - STAT5A AND STAT5B IN HEMATOPOIETIC AND LEUKEMIC STEM CELLS – BETWEEN DEATH AND IMMORTALITY / S. Kollmann* - M. Prchal-Murphy - B. Maurer - M. Farlik - V. Sexl

P227 - ADIPONECTIN DEFICIENCY SUPPRESSES LYMPHOMA GROWTH IN MICE BY MODULATING NK CELLS, CD8 T CELLS, AND MYELOID-DERIVED SUPPRESSOR CELLS / T. T. Chrisikos - B. Patel - K. Newton - L. K. Serrudo


P229 - IN VIVO LOSS OF IRF5 RESULTS IN SPONTANEOUS MAMMARY TUMORIGENESIS BY ALTERING METABOLISM AND GLOBAL MRNA TRANSLATION IN MAMMARY EPITHELIAL CELLS / S. Song* - D. Li - K. Kampta - M. Lapan - O. Guo - B. Barnes

P230 - ESTROGEN RECEPTORS REGULATE THE WNT/B-CATENIN SIGNALING PATHWAY IN CANCER BY TARGETING THE NOD-LIKE RECEPTORS / S. Ding - S. Liu
P231 - ESTROGEN RECEPTORS PARTICIPATE IN CARCINOGENSES SIGNALING PATHWAYS BY DIRECTLY REGULATING NOD-LIKE RECEPTORS / S. Song* - W. Fan


P236D - DUSP6 DEFICIENCY RESTRAINTS TCR-MEDIATED METABOLIC REPROGRAMMING WHICH CONFRONTS A SUPERIOR ANTI-TUMOR IMMUNITY / M.-Y. Chen* - W.-C. Hsu - Y.-W. Su


P236G - SELECTIVE STAT3 INHIBITION IN THE TUMOUR MICROENVIRONMENT RESTRICTS GASTROINTESTINAL TUMOUR GROWTH / M. Alorro* - M. Eismann - P. Masson - M. Ernst

P236H - ROLE OF TFH CELL DERIVED CYTOKINES IN ANTI-TUMOR IMMUNITY / R. Nurieva* - Z. Liu - Y.-Z. Zhao - M. Divenko - A. Alekseev


P239 - DOUBLE POSITIVE IL-17A/F+ T HELPER CELLS INDUCE INFLAMMATION AND RECRUITMENT NEUROPHILS IN TYPE 1 REACTION OF LEPROSY / C. Saini* - R. Srivasvata - V. Ramesh - A. Sharma


P241 - DECIPHERING THE ROLE OF TYROSINE KINASE 2 (TYK2) DURING CONTACT HYPERSENSIVITY / D. Acitores-Balboa* - C. Lassnig - A. Pözl - B. Strobl - M. Müller


P243 - PLASTICITY OF SKIN-RESIDENT COMMENSAL-SPECIFIC T CELLS PROMOTES TISSUE REPAIR / I. Rao* - N. Bouladoux - Y. Belkaid

P244 - IL-36 SIGNALING IN KERATINOCYTES IS MANDATORY IN IMIQUIMOD-INDUCED PSORIASIS IN MICE / J. Goldstein* - E. Y. Bassoy - J. Palomo - A. Caruso - E. Rodriguez - C. Gabay

P245 - DIFFERENTIAL EFFECTS OF IL-17A AND IL-17E (IL-25) ON EPIDERMAL HOMEOSTASIS / J. Borowczyk-Michalowska - W.-H. Boehncke - N. Brembilla - C. Buerger - J. Drukala - D. Wnuk - V. Lang - W.-H. Boehncke - N. C. Brembilla

P246 - PROPIONIBACTERIUM ACINES INDUCED INNATE IMMUNE RESPONSE IN HUMAN MACROPHAGES / K. Fischer* - R. Tschismarov - T. Decker


P248 - CHARACTERIZATION OF IL-24 EXPRESSION AND STUDY OF ITS ROLE IN CHRONIC SPONTANEOUS URTICARIA / M. Choteau* - L. de Montjoye - P. Cheou - E. Hendrickx - M. Baeck - L. Dumoutier

**P250 - T CELL DELETION OF MYD88 CONNECTS IL-17 AND IKBZ TO RAS ONCOCENESIS / R. Saito** - C. Katao - G. Trinchieri - S. H. Yuspa

**P251 - IL-17F AND IL-17A EQUALLY CONTRIBUTE TO THE PATHOGENESIS OF EXPERIMENTAL EPIDERMOLYSIS BULLOSA ACQUISITA / S. Jukic** - F. Deng - I. Prinz - B. Becher - A. Waisman - E. Schmidt - F. Petersen - C. Hölscher

**P252 - TYK2 SIGNALING IN IMMUNITY AGAINST CANDIDA ALBICANS SKIN INFECTIONS / S. Miranda** - N. Simonovic - C. Lassnig - A. Pözl - K. Kuchler - M. Müller - B. Strobl

**P253 - SIGNIFICANT INTERACTION BETWEEN PRE-IL-1A AND PRE-IL-3 CONTRIBUTES TO TISSUE FIBROSIS IN SYSTEMIC SCLEROSIS / Y. Kawaguchi** - T. Higuchi - K. Takagi - M. Harigai

**P254 - EFFECTS OF VACCINIA VIRUS-DRIVEN EXPRESSION OF INTERFERON REGULATORY FACTOR 3 ON PROTECTIVE IMMUNITY AGAINST LETHAL POXVIRAL INFECTION AND ON CYTOKINES EXPRESSED IN SKIN OF ATOPIC NC/NGA AND CONTROL BALB/C MICE / Z. Melkova** - V. Hajkova - H. Pilna

**P255 - TLR3 ACTIVATION REDUCES ANTIViral RESPONSE TRIGGERED BY RIG-LIKE RECEPTORS DURING ZIKA VIRUS INFECTION / A. Plociennikowska** - J. Frankish - T. Moraes - M. Binder - R. Bartenschlager

**P256 - IFNAR1 SIGNALING BREAKS THE HEPATIC - J. Frankish - T. Moraes - M. Binder - R. Bartenschlager


**P262 - ROLE OF IRF9 IN IMMUNE IMMUNITY AGAINST LISTERIA MONOCYTOGENES / D. Demiroz** - A. Lercher - A. Bergthaler - T. Decker


**P267 - TYK2 SIGNALING IN IMMUNITY AGAINST CANDIDA ALBICANS SKIN INFECTIONS / S. Miranda** - N. Simonovic - C. Lassnig - A. Pözl - K. Kuchler - M. Müller - B. Strobl

**P268 - TYK2 SIGNALING IN IMMUNITY AGAINST CANDIDA ALBICANS SKIN INFECTIONS / S. Miranda** - N. Simonovic - C. Lassnig - A. Pözl - K. Kuchler - M. Müller - B. Strobl


**P272 - IMBALANCED MYELOPOIESIS BY TREATMENT OF ANTI-CANCER DRUGS AGGRAVATES TUBERCULOSIS PROGRESSION / K. W. Kwon** - T. G. Kang - S.-J. Ha - S. J. Shin

**P273 - CNA ACTIVATION CAN IMPROVE NEONATAL INFANNE IMMUNE RESPONSES TO ALUM AND OTHER POTENTIAL VACCINE ADJUVANTS / K. Brennan** - S. Crenn - E. J. Molloy - P. T. Walsh - F. McAuliffe - S. L. Doyle


**P279 - NOD1 ACTIVATION CAN IMPROVE NEONATAL INNATE IMMUNE RESPONSES TO ALUM AND OTHER POTENTIAL VACCINE ADJUVANTS / K. Brennan** - S. Crenn - E. J. Molloy - P. T. Walsh - F. McAuliffe - S. L. Doyle


**P281 - TYK2 SIGNALING IN IMMUNITY AGAINST CANDIDA ALBICANS SKIN INFECTIONS / S. Miranda** - N. Simonovic - C. Lassnig - A. Pözl - K. Kuchler - M. Müller - B. Strobl


P286 - MID50, A NOVEL METHOD TO QUANTIFY TYPE I IFN / S. Han* - Y. Yang

P287 - ADIPOLECTIN DEFICIENCY PROMOTES CHRONIC INFLAMMATION DURING AGING THROUGH REGULATION OF INNATE IMMUNE CELLS AND MESENCHYMAL STEM CELLS IN BONE MARROW / S. Han* - Y. Yang


P289 - THE ROLE OF SELECTIVE AUTOPHAGY IN INTRACELLULAR INFECTIOUS BURSAL DISEASE VIRUS (IBDV) CLEARANCE / Y. Li* - C. Xu - J. Lei - B. Hu


P290 - SKIN INNATE ANTIMICROBIAL IMMUNITY IS REGULATED BY IFN-DEPENDENT AND IFN-INDEPENDENT MECHANISMS AND PROTECTS AGAINST FLAVIVIRUS INFECTION / A. S. Macleod* - J. Kwock - C. Handfield

P290A - ASC-MUTATED JAPANESE MEDAKA ORYZIAS LATIPES BY CRISPR-CAS9 SYSTEM OBTAINS RESISTANCE TO INFECTION OF EDWARDSIELLA PISCICIDA / J-I. Hikima* - N. Morimoto - Y. Okamura - T. Kono - M. Sakai
PBL Assay Science, your trusted source for interferon ELISAs, proteins, antibodies, and assay services is proud to be a sponsor for the Cytokines 2019 Conference.

We invite you to visit us in the Conference Exhibit Hall and poster presentation (no. P204A) to discover how our IFN Alpha All-Subtype ELISA kits and other offerings can help you in your research.

**CONDUCT YOUR**

**Experimental Symphony**

with PBL’s Assay Solutions!
**Company Profiles**

**Abcam**

Email: info@abcam.com  
Website: www.abcam.com  
Phone: +1 617 577 42 00

As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster. Please visit: www.abcam.com

---

**AYOXXA Biosystems GmbH**

Email: sales@ayoxxa.com  
Website: www.ayoxxa.com  
Phone: +49 221 222 52 90

AYOXXA Biosystems GmbH is an international life science company with headquarters in Cologne (Germany). With LUNARIS(TM), its proprietary beads-on-a-chip multiplexing platform the Company is paving the way for translating knowledge generated in a laboratory environment through clinical studies in support of basic biology and drug development. LUNARIS(TM) enables fully scalable quantitative validation of biomarkers in minute amounts of biological samples. AYOXXA is commercializing a growing portfolio of standardized ready-to-use biomarker assays, with a focus on the biology of inflammation and immune response.

---

**BioLegend**

Email: robertadams@biolegend.com  
Website: www.biolegend.com  
Phone: +1 858 455 95 88

BioLegend enables life science discovery from research to cure by providing world-class quality biological reagents and tools at an outstanding value, with highly acclaimed customer service and technical support. Our portfolio includes research tools for cancer, immunology, neuroscience, cell biology, and stem cells. We offer 700+ bioassay-validated recombinant cytokines and growth factors, and LEGENDplex™ bead-based immunoassays to quantify multiple soluble analytes simultaneously using a flow cytometer. BioLegend operates under an ISO 13485:2016 certified quality management system.

---

**Bio-Techne®**

Email: kate.wilmore@bio-technne.com  
Website: www.bio-technne.com  
Phone: +44 123 552 94 49


---

**Bon Opus Biosciences**

Email: marketing@bonopusbio.com  
Website: www.bonopusbio.com  
Phone: +1 800 943 63 96

Bon Opus Biosciences is an NJ-based Contract Research Organization. Our areas of expertise include gene synthesis, custom protein expression, and custom antibody production. All proteins have activity and purity data testing performed and reported. In addition to our vast recombinant protein catalog featuring up to 2,000 protein products, we also carry a comprehensive catalog of over 3,000 primary antibodies, both monoclonal and polyclonal. Bon Opus has built several service programs that are specifically designed to support the development of targeted therapeutics - in particular, antigen production and monoclonal antibodies.

---

**Bristol-Myers Squibb**

Website: www.bms.com

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our people are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunology and fibrosis. Through the Bristol-Myers Squibb Foundation, we promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people. Each day, our employees around the world work together for patients – it drives everything we do.
Eli Lilly Ges.m.b.H
Email: lilly_aut@lilly.com
Website: www.lilly.at
Phone: +43 1 711 78-0 (office)
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com

Elsevier
Email: ursula@pennedby.com
Website: www.elsevier.com
Leading the way in advancing science, technology and health. Elsevier helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Combining content with technology, supported by operational efficiency, Elsevier turns information into actionable knowledge. Elsevier empowers knowledge which empowers those who use it.

European Federation of Immunological Societies (EFIS)
Email: office@efis.org
Website: www.efis.org
EFIS unites 35 European national immunological societies and their 14,000 individual members, pursuing its mission to advance education, training, research and collaboration in immunology and related fields. With its partner journal, the European Journal of Immunology, EFIS offers financial support to the organizers of high-caliber immunology-related international meetings, workshops and schools to enhance interaction between young scientists and established immunologists, funding the participation costs of junior researchers who would otherwise be unable to attend quality immunology-themed events.

Genentech, Inc.
Email: immunologyTA@its.jnj.com
Website: www.janssen.com/immunology
At Janssen, we are relentlessly dissatisfied with the status quo since, despite significant advances, there is still immense unmet need among those living with immune-mediated disease. Our vision is a future where the millions of people living with immune-mediated disease experience a lifetime of vibrant health. To make that future a reality, we operate at the intersection of unmet need, deep disease insights and novel pathway science, persistently pushing the boundaries of science and creativity to deliver transformational approaches that redefine the treatment of immune-mediated diseases.

Mary Ann Liebert, Inc.
Email: slewis@liebertpub.com
Website: www.liebertpub.com
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research, including Journal of Interferon & Cytokine Research, OMICS: A Journal of Integrative Biology, Journal of Computational Biology, and Zebrafish. These publications play an active and vital role in advancing critical research and facilitating collaboration throughout the world in academia, industry, and government, and are also highly respected resources for legislators, policy makers, and educators.
Nektar scientists are committed in their quest to discover ground-breaking therapies.
Meso Scale Discovery
Email: tradeshows@mesoscale.com
Website: www.mesoscale.com
Phone: +1 240 314 26 00
Meso Scale Discovery (MSD®) is a leader in high performance, multiplex-enabled biomarker assays for cytokines, toxicology, neurodegeneration and metabolic disease research, used by leading biopharmaceutical and academic researchers in human and animal model studies. MSD™s proprietary electrochemiluminescence (ECL) platform delivers exceptional sensitivity, wide dynamic range and rapid turnaround. For more information, visit www.mesoscale.com.

Nektar Therapeutics
Website: www.nektar.com
Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, autoimmune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Further information about the company and its drug development programs and capabilities may be found online at nektar.com.

Novartis
Website: www.novartis.com
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105 thousand people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

PBL Assay Science
Email: info@pblassaysci.com
Website: www.pblassaysci.com
PBL Assay Science works hand in hand with researchers to help solve difficult assay development and protein quantification problems. Known as a trusted source for high quality, high sensitivity ELISAs as well as interferon proteins and antibodies for more than 30 years, we provide cytokine assay solutions that include low-picogram IFN ELISA kits, unique cytokine multiplex ELISA kits, high quality protein and antibody reagents, and assay services to scientists around the world. From accurate detection of human IFN-beta in autoimmune disease sera to sub-picogram cytokine assays, our products and services are designed to provide you with highly reproducible results.

Pfizer Inc.
Website: www.pfizer.com
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

Quanterix Corporation
Email: info@quanterix.com
Website: www.quanterix.com
Phone: +1 617 301 94 00
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to today’s approach to healthcare by giving researchers the ability to closely examine the continuum from health to disease. Simoa technology is designed to enable earlier disease detection and enhanced treatment methods to improve the quality of life and longevity for generations to come. Simoa is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation, and more.
Company Profiles

Regeneron
Website: www.regeneron.com
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Society & Journal for Leukocyte Biology
Email: jholland@leukocytebiology.org
Website: www.leukocytebiology.org
Phone: +30 12 04 22 33
The Society for Leukocyte Biology (SLB) is a community of like-minded researchers and clinicians. Emphasizing supporting members, SLB provides numerous opportunities to present and publish at conferences and through the Journal of Leukocyte Biology. Numerous committees include opportunities to gain experience and lead the direction of the organization. SLB organizes workshops providing professional development training. An extensive awards program supports members from many backgrounds. Mentoring support is included to foster the growth of trainees. SLB provides these services while growing globally and expanding opportunities for member to member collaboration.

Swedish Orphan Biovitrum GmbH
Email: mail.de@sobi.com
Website: www.sobi-deutschland.de
Phone: +49 895 506 67 60
At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised international biopharmaceutical company, we provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases a belief in the strength of focus, the power of agility and the potential of the people we are dedicated to serving.

Thermo Fisher Scientific
Website: www.thermofisher.com
Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. Through our premier brands Thermo Scientific, Applied Biosystems, Invitrogen and Gibco brands we offer an unmatched combination of innovative technologies to help our customers accelerate life science research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity.
We’re in the business of patients, not patience.

We like to think it’s our commitment to bold breakthrough innovations, along with a healthy dose of impatience, that has helped us develop and introduce five medicines for immune-mediated diseases. Another way we are creating a future where disease is a thing of the past. Learn more at www.janssen.com.

We’re hiring! Learn how to join our team at www.careers.jnj.com
Layout of Venue & Exhibition Area

COMPANY NAMES & BOOTH NUMBERS

ABCAM 10  Leukocyte Biology  B
AYOXXA Biosystems GmbH 11  Meso Scale Discovery  5
Bio Techne 1  PBL Assay Science  6
BioLegend 4  Quanterix  2
Bon Opus Biosciences 7  Swedish Orphan Biovitrum GmbH  8
International Cytokine & Interferon Society  A  Thermo Fischer Scientific  3
Janssen 9
Acknowledgements

PLATINUM SPONSORS

Bristol-Myers Squibb
CHUGAI
Roche Group
Lilly
Pfizer

GOLD SPONSORS

AstraZeneca
Janssen Immunology
NEKTAR
Novartis

SILVER SPONSORS

BioLegend
pbl
Regeneron

OTHER SPONSORS, EXHIBITORS & MEDIA PARTNERS

abcam
AYOXXA
biotechne
Bon-Opus
CSF
Elsevier
Genentech
ICIS
InvivoGen
JSiCR
Society for Leukocyte Biology
Journal of Interferon & Cytokine Research
M&O
Quanterix
JEM
Science Immunology
Sobi
ThermoFisher Scientific

48
Novartis

Supporting the rheumatology community to improve patients’ lives

- Partnering to further understand the basic research needs of disease
- Cooperating with the rheumatology community to better understand remission
- Supporting medical education initiatives
- Introducing innovation and technology into our clinical trial designs
- Collaborating with national registries
- Initiating non-interventional studies
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

REGENERON.COM
@ REGENERON
A NEW PATHWAY THAT COULD HELP TREAT IMMUNE-MEDIATED DISEASES?

Bristol-Myers Squibb is committed to researching and developing innovative new treatments that can help better address unmet patient needs. With an increased understanding of immune-mediated and inflammatory pathways, BMS is identifying novel new targets that could potentially evolve the way we help patients.